4.7 Article

Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy-Induced Gastrointestinal Injury

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 79, Issue 2, Pages 116-128

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2021.10.028

Keywords

antiplatelet therapy; endoscopy; gastrointestinal injury; percutaneous coronary intervention

Funding

  1. China National Key RD Project [2016YFC1301300, 2016YFC1301303]
  2. Ankon Medical Technologies, Shanghai, China

Ask authors/readers for more resources

This study assessed the effects of different antiplatelet regimens on gastrointestinal mucosal injury in patients at low bleeding risk using a novel capsule endoscopy system.
BACKGROUND Gastrointestinal bleeding is the most frequent major complication of antiplatelet therapy. In patients at tow bleeding risk, however, clinically overt gastrointestinal bleeding is relatively uncommon. OBJECTIVES The authors sought to assess the effects of different antiplatelet regimens on gastrointestinal mucosal injury by means of a novel magnetically controlled capsule endoscopy system in patients at tow bleeding risk. METHODS Patients (n 505) undergoing percutaneous coronary intervention in whom capsule endoscopy demonstrated no ulcerations or bleeding (although erosions were permitted) after 6 months of dual antiplatelet therapy (DAPT) were randomly assigned to aspirin plus placebo (n 168), clopidogrel plus placebo (n = 169), or aspirin plus clopidogrel (n 168) for an additional 6 months. The primary endpoint was the incidence of gastrointestinal mucosal injury (erosions, ulceration, or bleeding) at 6-month or 12-month capsule endoscopy. RESULTS Gastrointestinal mucosal injury through 12 months was less with single antiplatelet therapy (SAPT) than with DAPT (94.3% vs 99.2%; P = 0.02). Aspirin and clopidogrel monotherapy had similar effects. Among 68 patients without any gastrointestinal injury at randomization (including no erosions), SAPT compared with DAPT caused less gastrointestinal injury (68.1% vs 95.2%; P = 0.006), including fewer new ulcers (8.5% vs 38.1%; P = 0.009). Clinical gastrointestinal bleeding from 6 to 12 months was less with SAPT than with DAPT (0.6% vs 5.4%; P = 0.001). CONCLUSIONS Despite being at tow risk of bleeding, nearly alt patients receiving antiplatelet therapy developed gastrointestinal injury, although overt bleeding was infrequent. DAPT for 6 months followed by SAPT with aspirin or dopidogret from 6 to 12 months resulted in less gastrointestinal mucosat injury and clinical bleeding compared with DAPT through 12 months. (OPT-PEACE [Optimal Antiplatelet Therapy for Prevention of Gastrointestinal Injury Evaluated by Ankon Magnetically Controlled Capsule Endoscopy]) (C) 2022 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available